Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concizumab prophylaxis in hemophilia A or B with inhibitors
2023-506832-33-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of concizumab in hemophilia A and hemophilia B (HB) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treated spontaneous and traumatic bleeding episodes. Planned start Nov 2019; status: authorised.
02
Drugs
concizumab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2023-506832-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506832-33-00.